Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for
pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the
rapid development, clinical assessment and commercial readiness of its DRGT-
46 product using integrated services across Quotient’s network of harmonized
development and manufacturing sites in the UK and US.